Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proprietary drug names meeting

This article was originally published in The Tan Sheet

Executive Summary

Public meeting on "Minimizing Medication Errors - Methods for Evaluating Proprietary Names for Their Confusion Potential" will be held June 26 by FDA, PhRMA, Institute for Safe Medication Practices (ISMP), according to 1May 30 Federal Register notice. Goal of meeting is to solicit views on FDA recommendation that drug manufacturers "perform proprietary name testing prior to submitting NDAs and ANDAs," agency says. Input from workshop, other comments "may be considered in developing a draft guidance on this topic," FDA adds...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS095532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel